GSK

1,403.5

+0.43%↑

INDV

985.5

-2.43%↓

GSK

1,403.5

+0.43%↑

INDV

985.5

-2.43%↓

GSK

1,403.5

+0.43%↑

INDV

985.5

-2.43%↓

GSK

1,403.5

+0.43%↑

INDV

985.5

-2.43%↓

GSK

1,403.5

+0.43%↑

INDV

985.5

-2.43%↓

Search

AstraZeneca PLC

Open

SectorHealthcare

10,192 0.06

Overview

Share price change

24h

Current

Min

10148

Max

10260

Key metrics

By Trading Economics

Income

1.3B

2.9B

Sales

-1.3B

14B

P/E

Sector Avg

28.239

50.291

EPS

148.337

Dividend yield

2.36

Profit margin

21.46

Employees

94,300

EBITDA

648M

5.1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+29.39% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.36%

2.40%

Next Earnings

29 lip 2025

Next Dividend date

8 wrz 2025

Next Ex Dividend date

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

-21B

162B

Previous open

10191.94

Previous close

10192

News Sentiment

By Acuity

41%

59%

136 / 380 Ranking in Healthcare

AstraZeneca PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 maj 2025, 09:36 UTC

Major Market Movers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 kwi 2025, 10:14 UTC

Earnings

Correction to AstraZeneca Update

29 kwi 2025, 09:15 UTC

Earnings

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 kwi 2025, 08:12 UTC

Earnings

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 kwi 2025, 06:32 UTC

Earnings

AstraZeneca Sales, Earnings Rise

24 mar 2025, 03:15 UTC

Major Market Movers

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

28 maj 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New -2-

28 maj 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

20 maj 2025, 06:09 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Completes Acquisition of EsoBiotec

12 maj 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 maj 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 maj 2025, 15:20 UTC

Earnings

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 kwi 2025, 13:09 UTC

Market Talk
Earnings

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 kwi 2025, 08:04 UTC

Market Talk
Earnings

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 kwi 2025, 06:05 UTC

Earnings

AstraZeneca 1Q Core EPS $2.49

29 kwi 2025, 06:04 UTC

Earnings

AstraZeneca 1Q Net Pft $2.92B

29 kwi 2025, 06:02 UTC

Earnings

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 kwi 2025, 06:00 UTC

Earnings

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 kwi 2025, 06:00 UTC

Earnings

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 kwi 2025, 06:00 UTC

Earnings

AstraZeneca Backs 2025 View

29 kwi 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q EPS $1.87

29 kwi 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Rev $13.59B

29 kwi 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Oper Pft $3.67B

29 kwi 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 kwi 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 kwi 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 kwi 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 kwi 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 kwi 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mar 2025, 09:31 UTC

Hot Stocks

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

Peer Comparison

Price change

AstraZeneca PLC Forecast

Price Target

By TipRanks

29.39% upside

12 Months Forecast

Average 13,125 GBX  29.39%

High 16,500 GBX

Low 10,900 GBX

Based on 15 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

11

Buy

4

Hold

0

Sell

Sentiment

By Acuity

136 / 380 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.